Live Breaking News & Updates on Nureca

Stay informed with the latest breaking news from Nureca on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Nureca and stay connected to the pulse of your community

Nureca Ltd Q4FY23 consolidated loss at Rs. 1.53 crore

The Board of Directors of Nureca Limited, at its meeting held today have approved the financial results of the company for the period ended March 31, 2023 - Q4FY23 and FY2023.

Nureca-ltd , Year-ended , Financial-year , Nureca-limited , Nureca , Q4fy23 , Fy2023 , Resultupdate ,

Nureca Stock Discussion Forum Online India, Can i buy Nureca, Should i buy Nureca, Do i buy Nureca?

Browse Nureca stock discussion, ideas, questions and answers online at Moneycontrol.com.

Ltd-all , Nureca , Ani-buy-nureca , Houldi-buy-nureca , Oi-buy-nureca-moneycontrol ,

Nureca Ltd Q3 FY2023 consolidated net profit at Rs. 30.1 lakhs

The Board of Directors of Nureca Limited, at its meeting held today have approved the financial results of the company for the period ended December 31, 2022 - Q3FY23 and 9MFY23.

Nureca-ltd , Nureca-limited , Nureca , Q3fy23 , 9mfy23 , Resultupdate ,

Nureca share price hits 52-week low on bulk deal by promoter Payal Goyal

Shares of digital health and wellness company, Nureca, hit 52-week low at ₹525 after the promoter sold 55,863 shares at ₹546 apiece

Nureca , Dr-trust , Nureca-stock-price , Nureka-bulk-deal , Nureca-share-price-at-52-weeks-low , Healthcare-and-wellness-company ,

Nureca shares hit all-time low after promoter sells stake

Nureca stock hit a fresh low of Rs 525, down 2.48% against the previous close of Rs 538.35 on BSE. The stock opened lower at Rs 536 on BSE

Payal-goyal , Nureca-ltd , Gland-pharma , Nureca , Ureca-share-price , Ureca-shares-fall , Ayal-goyal-offloads-stake , Ureca-stock-falls , Ureca-stock-bulk-deal , Ureca-share , Ureca-stock , Ayal-goyal-sells-nureca-shares

This recently-listed healthcare stock has zoomed 132% against issue price

Shares of the recently-listed healthcare supplies company Nureca rallied 10 per cent and hit a new high of Rs 929 on the BSE on Monday in an otherwise weak market. At 01:48 pm, it was trading 7 per cent higher at Rs 906, against 3.5 per cent decline in the S&P BSE Sensex.
In the past three days, the stock of the home healthcare and wellness products provider has jumped 36 per cent and soared 132 per cent against its issue price of Rs 400 per share. Nureca’s Rs 100-crore IPO had seen more than 40 times oversubscription.
As per the shareholding pattern, out of the 30 per cent public shareholding, institutional investors held 18.72 per cent stake in Nureca. Individual shareholders held 5.87 per cent holding, while bodies corporate and Yash Shares and Stock Private Limited held 5.30 per cent and 4.41 per cent stake, respectively.

India , Tata-group , Stock-private , Yash-shares , Stock-private-limited , Pulse-oximeters , Nureca-share-price , Markets , Health-care , Ipo , Nureca

Home First, Heranba, Brookfield, Nureca hit lowest levels since debut

Shares of recently listed companies, Home First Finance Company, Heranba Industries, Brookfield India Real Estate Trust REIT and Nureca hit their respective lows since listing on the bourses. These stocks were down between 2 per cent and 8 per cent on the BSE in the intra-day trade on Monday. In comparison, the S&P BSE Sensex was down 1.7 per cent at 49,925 points at 02:04 pm.
Shares of agrochemicals company Heranba Industries, for instance, slipped 7 per cent to Rs 708 on the BSE. With today’s fall, the stock has declined 25 per cent from its listing day high of Rs 945 hit on March 5, 2021. The stock had made a strong debut at Rs 900, a 43.5 per cent premium against the issue price of Rs 627 per share.

Heranba-industries , Home-first-finance-company , Embassy-office-parks , Brookfield-india-real-estate-trust , Brookfield-india-real-estate-investment-trust , Brookfield-india , Real-estate-investment-trust , Business-parks , Brookfield-india-real-estate-trust-reit , Nureca , Ipo

Nureca spurts on debut

Read more about Nureca spurts on debut on Business Standard. Shares of Nureca hit an upper circuit of 5% at Rs 666.65 at 10:17 IST on the BSE, a premium of 66.66% over the initial public offer price of Rs 400.

India , Capital-market , Home-healthcare , Wellness-products , Nureca , Retail-individual-investors-category , Home-healthcare-sector , General-corporate-purposes , இந்தியா , மூலதனம்-சந்தை , வீடு-சுகாதாரம்

Axis Bank, Nureca, Just Dial in spotlight

Shares of Axis Bank will be in focus. Max Life has received the formal approval from the Insurance Regulatory and Development Authority of India (IRDAI), which vide its letter dated 24th February 2021 has granted approval to the Axis Entities, as promoters of Max Life, to collectively acquire 12.002% of the equity share capital of Max Life, by way of transfer of equity shares of Max Life from Max Financial to the Axis Entities.
Shares of Nureca will debut on bourses today, 25 February 2021. The final issue price was fixed at Rs 400 per share.
Just Dial has launched its B2B portal, Jd Mart, across various platforms for users. Jd Mart is an exclusive B2B portal for a new wholesale experience. B2B buyers can discover quality vendors offering a wide selection of products to choose from, spread across various categories to suit all their B2B needs.

Cochin , Kerala , India , Netherlands , Holland , Axis-bank , Cochin-shipyard , Corporation-of-india , Development-authority-of-india , Insurance-regulatory , Development-authority

Shares of wellness product seller Nureca soar 61% on debut, end at Rs 645

Read more about Shares of wellness product seller Nureca soar 61% on debut, end at Rs 645 on Business Standard. Issue price was Rs 400 per share. Nureca's Rs 100-crore IPO was oversubscribed 40x

Nureca , Nureca-shares , Nureca-debut , Nureca-listing , Nureca-investment ,